Adjuvant therapy for lung neuroendocrine neoplasms

Area of Science:

• Pulmonology
• Oncology
• Cancer Research

Background:

• Pulmonary neuroendocrine neoplasms (NENs) encompass a spectrum of lung cancers, from indolent pulmonary carcinoid (PC) tumors to aggressive small cell lung cancer (SCLC).
• SCLC constitutes up to 15% of lung cancers, while PCs are rarer, accounting for approximately 2%.

Purpose of the Study:

• To discuss the role and review the available literature on adjuvant therapy in pulmonary neuroendocrine neoplasms (NENs).
• To address the current guidelines and evidence gaps regarding adjuvant treatment for different NEN subtypes.

Main Methods:

• Literature review of existing studies and clinical guidelines concerning adjuvant therapy for pulmonary neuroendocrine neoplasms.
• Analysis of treatment standards for early-stage pulmonary carcinoid (PC), large cell neuroendocrine carcinoma (LCNEC), and small cell lung cancer (SCLC).

Main Results:

• Surgical resection is the standard for early-stage PCs and is considered for early-stage LCNEC and SCLC.
• Adjuvant treatment is generally accepted for aggressive LCNEC and SCLC.
• Evidence supporting adjuvant therapy for PCs is less established, with guidelines noting a lack of supporting trials.

Conclusions:

• The role of adjuvant therapy varies significantly across pulmonary neuroendocrine neoplasm subtypes.
• Further clinical trials are needed to establish high-level recommendations for adjuvant therapy, particularly for pulmonary carcinoid tumors.